Benzinga | Nov 5, 2021 09:43AM EDT

Wedbush Upgrades IGM Biosciences to Outperform, Announces $82 Price Target

Wedbush analyst Robert Driscoll upgrades IGM Biosciences (NASDAQ:IGMS) from Neutral to Outperform and announces $82 price target.